The DOI matches its Crossref record; 50 of the 50 references it cites were found in a registry or an index.
Therapeutic Effects of Coenzyme Q10and Remacemide in Transgenic Mouse Models of Huntington's Disease
Open accessAbstract
There is substantial evidence that bioenergetic defects and excitotoxicity may play a role in the pathogenesis of Huntington's disease (HD). Potential therapeutic strategies for neurodegenerative diseases in which there is reduced energy metabolism and NMDA-mediated excitotoxicity are the administration of the mitochondrial cofactor coenzyme Q10 and the NMDA antagonist remacemide. We found that oral administration of either coenzyme Q10 or remacemide significantly extended survival and delayed the development of motor deficits, weight loss, cerebral atrophy, and neuronal intranuclear inclusions in the R6/2 transgenic mouse model of HD. The combined treatment, using coenzyme Q10 and remacemide together, was more efficacious than either compound alone, resulting in an approximately 32 and 17% increase in survival in the R6/2 and N171-82Q mice, respectively. Magnetic resonance imaging showed that combined treatment significantly attenuated ventricular enlargement in vivo. These studies further implicate defective energy metabolism and excitotoxicity in the R6/2 and N171-82Q transgenic mouse models of HD and are of interest in comparison with the outcome of a recent clinical trial examining coenzyme Q10 and remacemide in HD patients.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Similarly, we and others, by using CoQ10 and remacemide (NMDA antagonist) combination therapy observed significantly improved motor performance and increased survival in the R6/2 and the N-171-82Q transgenic mouse models of HD151, 154.”
From Mitochondrial Approaches for Neuroprotection (2008) · cites this paper as [151]
In the citing paper
“We also demonstrated that CoQ10 produces neuroprotective effects in transgenic mouse models of ALS and HD150, 151.”
From Mitochondrial Approaches for Neuroprotection (2008) · cites this paper as [151]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The Mouse Brain in Stereotaxic Coordinates
Paxinos, G. (2001) · Cited by 12,859
MACDONALD, M. (1993) · Cell · doi:10.1016/0092-8674(93)90585-e · Cited by 8,366
mouse brain in stereotaxic coordinates
Franklin, K. B. J., & Paxinos, G. (1997) · Cited by 3,258
Mangiarini, L., Sathasivam, K., Seller, M., Cozens, B., Harper, A., Hetherington, C., Lawton, M., Trottier, Y., Lehrach, H., Davies, S. W., et al. (1996) · Cell · doi:10.1016/s0092-8674(00)81369-0 · Cited by 3,073
Shah, M. A., Datson, N. A., Srinidhi, L., Stanton, V. P., MacDonald, M. E., Allard, M. W., Youngman, S., Am, F., Mott, R., Draths, K., et al. (1993) · Cell · Cited by 3,055
Self-citationDavies, S. W., Turmaine, M., Cozens, B. A., DiFiglia, M., Sharp, A. H., Ross, C. A., Scherzinger, E., Wanker, E. E., Mangiarini, L., & Bates, G. P. (1997) · Cell · doi:10.1016/s0092-8674(00)80513-9 · Cited by 2,188
Replication of the neurochemical characteristics of Huntington's disease by quinolinic acid
Beal, M. F., Kowall, N. W., Ellison, D. W., Mazurek, M. F., Swartz, K. J., & Martin, J. B. (1986) · Nature · doi:10.1038/321168a0 · Cited by 1,287
Self-citationChen, M., Ona, V. O., Li, M., Ferrante, R. J., Fink, K., Zhu, S., Bian, J., Guo, L., Farrell, L. A., Hersch, S. M., et al. (2000) · Nature Medicine · doi:10.1038/77528 · Cited by 1,060
Self-citationBeal, M. F., Brouillet, E., Jenkins, B. G., Ferrante, R. J., Kowall, N. W., Miller, J., Storey, E., Srivastava, R., Rosen, B. R., & Hyman, B. T. (1993) · Journal of Neuroscience · doi:10.1523/jneurosci.13-10-04181.1993 · Cited by 1,026
Self-citationBrowne, S. E., Bowling, A. C., Macgarvey, U., Baik, M. J., Berger, S. C., Muquit, M. M. K., Bird, E. D., & Beal, M. F. (1997) · Annals of Neurology · doi:10.1002/ana.410410514 · Cited by 885
Self-citation
Cited by
Sorted by citations
Ravikumar, B., Vacher, C., Berger, Z., Davies, J. E., Luo, S., Oroz, L. G., Scaravilli, F., Easton, D. F., Duden, R., O'Kane, C. J., et al. (2004) · Nature Genetics · doi:10.1038/ng1362 · Cited by 2,347
Molecular Mechanisms and Potential Therapeutical Targets in Huntington's Disease
Zuccato, C., Valenza, M., & Cattaneo, E. (2010) · Physiological Reviews · doi:10.1152/physrev.00041.2009 · Cited by 848
Hockly, E., Richon, V. M., Woodman, B., Smith, D. L., Zhou, X., Rosa, E., Sathasivam, K., Ghazi‐Noori, S., Mahal, A., Lowden, P. A. S., et al. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0437870100 · Cited by 847
Ferrante, R. J., Kubilus, J. K., Lee, J.-H., Ryu, H., Beesen, A. A., Zucker, B., Smith, K., Kowall, N. W., Ratan, R. R., Luthi‐Carter, R., et al. (2003) · Journal of Neuroscience · doi:10.1523/jneurosci.23-28-09418.2003 · Cited by 705
Self-citationHarper, S. Q., Staber, P. D., He, X., Eliason, S. L., Martins, I. H., Mao, Q., Yang, L., Kotin, R. M., Paulson, H. L., & Davidson, B. L. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0501507102 · Cited by 682
Huntington’s Disease: Mechanisms of Pathogenesis and Therapeutic StrategiesPreprint
Jiménez-Sánchez, M., Licitra, F., Underwood, B. R., & Rubinsztein, D. C. (2016) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a024240 · Cited by 528
Mattson, M. P. (2003) · NeuroMolecular Medicine · doi:10.1385/nmm:3:2:65 · Cited by 479
Gárdián, G., Browne, S. E., Choi, D., Klivènyi, P., Gregorio, J., Kubilus, J. K., Ryu, H., Langley, B. C., Ratan, R. R., Ferrante, R. J., et al. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m410210200 · Cited by 456
Self-citationMinocycline and Neurodegenerative Diseases
Kim, H.-S., & Suh, Y.-H. (2009) · Behavioural Brain Research · doi:10.1016/j.bbr.2008.09.040 · Cited by 447
Oxidative stress and mitochondrial dysfunction in neurodegenerative diseases
Trushina, E. V., & McMurray, C. T. (2007) · Neuroscience · doi:10.1016/j.neuroscience.2006.10.056 · Cited by 451
Okamoto, S., Pouladi, M. A., Talantova, M. V., Yao, D., Xia, P., Ehrnhoefer, D. E., Zaidi, R., Clemente, A., Kaul, M., Graham, R. K., et al. (2009) · Nature Medicine · doi:10.1038/nm.2056 · Cited by 449
de Vries, H. E., Witte, M. E., Hondius, D., Rozemüller, A. J. M., Drukarch, B., Hoozemans, J. J. M., & van Horssen, J. (2008) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2008.09.001 · Cited by 436
Mitochondrial Diseases of the Brain
Chaturvedi, R. K., & Beal, M. F. (2013) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2013.03.018 · Cited by 426
Self-citationHuntington's disease: from pathology and genetics to potential therapies
Imarisio, S., Carmichael, J., Korolchuk, V., Chen, C.-W., Saiki, S., Rose, C., Krishna, G., Davies, J. E., Ttofi, E., Underwood, B. R., et al. (2008) · Biochemical Journal · doi:10.1042/bj20071619 · Cited by 409
Redox Signaling by Reactive Electrophiles and Oxidants
Parvez, S., Long, M. J. C., Poganik, J. R., & Aye, Y. (2018) · Chemical Reviews · doi:10.1021/acs.chemrev.7b00698 · Cited by 368
Canals, J. M., Pineda, J. R., Torres-Peraza, J. F., Bosch, M., Martín‐Ibáñez, R., Muñoz, M. T., Mengod, G., Ernfors, P., & Alberch, J. (2004) · Journal of Neuroscience · doi:10.1523/jneurosci.1197-04.2004 · Cited by 345
Boudreau, R. L., McBride, J. L., Martins, I., Shen, S., Xing, Y., Carter, B. J., & Davidson, B. L. (2009) · Molecular Therapy · doi:10.1038/mt.2009.17 · Cited by 340
Therapeutic Effects of Cystamine in a Murine Model of Huntington's Disease
Dedeoglu, A., Kubilus, J. K., Jeitner, T. M., Matson, S. A., Bogdanov, M., Kowall, N. W., Matson, W. R., Cooper, A. J. L., Ratan, R. R., Beal, M. F., et al. (2002) · Journal of Neuroscience · doi:10.1523/jneurosci.22-20-08942.2002 · Cited by 317
Self-citationKeene, C. D., Rodrigues, C. M. P., Eich, T., Chhabra, M. S., Steer, C. J., & Low, W. C. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.162362299 · Cited by 306
Mitochondrial Approaches for Neuroprotection
Chaturvedi, R. K., & Beal, M. F. (2008) · Annals of the New York Academy of Sciences · doi:10.1196/annals.1427.027 · Cited by 294
Self-citationMitochondria in Huntington's disease
Damiano, M. G., Galvan, L., Déglon, N., & Brouillet, E. (2009) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2009.07.012 · Cited by 295
Weight loss in early stage of Huntington’s disease
Djoussé, L., Knowlton, B. A., Cupples, L. A., Marder, K. S., Shoulson, I., & Myers, R. H. (2002) · Neurology · doi:10.1212/01.wnl.0000031791.10922.cf · Cited by 284
Reactive Oxygen Species: Stuck in the Middle of Neurodegeneration
Patten, D. A., Germain, M., Kelly, M., & Slack, R. S. (2010) · Journal of Alzheimer s Disease · doi:10.3233/jad-2010-100498 · Cited by 286
Beal, M. F. (2004) · Journal of Bioenergetics and Biomembranes · doi:10.1023/b:jobb.0000041772.74810.92 · Cited by 277
Self-citationSlow, E., Graham, R. K., Osmand, A. P., Devon, R. S., Lu, G., Deng, Y. L., Pearson, J., Vaid, K., Bissada, N., Wetzel, R. B., et al. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0503634102 · Cited by 286
Endogenous synthesis of coenzyme Q in eukaryotes
Tran, U. C., & Clarke, C. F. (2007) · Mitochondrion · doi:10.1016/j.mito.2007.03.007 · Cited by 266
Mutant Huntingtin Causes Context-Dependent Neurodegeneration in Mice with Huntington's Disease
Yu, Z.-X., Li, S.-H., Evans, J., Pillarisetti, A., He, L., & Li, X. (2003) · Journal of Neuroscience · doi:10.1523/jneurosci.23-06-02193.2003 · Cited by 260
Novak, M. J. U., & Tabrizi, S. J. (2010) · BMJ · doi:10.1136/bmj.c3109 · Cited by 255
Sp1 and Sp3 Are Oxidative Stress-Inducible, Antideath Transcription Factors in Cortical Neurons
Ryu, H., Lee, J.-H., Zaman, K., Kubilis, J., Ferrante, R. J., Ross, B. D., Neve, R. L., & Ratan, R. R. (2003) · Journal of Neuroscience · doi:10.1523/jneurosci.23-09-03597.2003 · Cited by 251
Self-citationCalkins, M. J., Jakel, R. J., Johnson, D. A., Chan, K., Kan, Y. W., & Johnson, J. A. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0408487101 · Cited by 247
Antioxidant and bioenergetic coupling between neurons and astrocytes
Fernandez-Fernandez, S., Almeida, A., & Bolaños, J. P. (2012) · Biochemical Journal · doi:10.1042/bj20111943 · Cited by 247
Stack, E. C., Kubilus, J. K., Smith, K., Cormier, K., Signore, S. J. D., Guélin, E., Ryu, H., Hersch, S. M., & Ferrante, R. J. (2005) · The Journal of Comparative Neurology · doi:10.1002/cne.20680 · Cited by 255
Self-citationThe Energetics of Huntington's Disease
Browne, S. E., & Beal, M. F. (2004) · Neurochemical Research · doi:10.1023/b:nere.0000014824.04728.dd · Cited by 240
Self-citationBioenergetic approaches for neuroprotection in Parkinson's disease
Beal, M. F. (2003) · Annals of Neurology · doi:10.1002/ana.10479 · Cited by 236
Self-citationMismatch repair gene Msh2 modifies the timing of early disease in HdhQ111 striatum
Wheeler, V. C. (2003) · Human Molecular Genetics · doi:10.1093/hmg/ddg056 · Cited by 232
Yang, L., Calingasan, N. Y., Wille, E. J., Cormier, K., Smith, K., Ferrante, R. J., & Beal, M. F. (2009) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2009.06074.x · Cited by 237
Self-citationHuntington's Disease: Can Mice Lead the Way to Treatment?
Crook, Z. R., & Housman, D. E. (2011) · Neuron · doi:10.1016/j.neuron.2010.12.035 · Cited by 236
Huntington’s disease: from huntingtin function and dysfunction to therapeutic strategies
Borrell-Pagés, M., Zala, D., Humbert, S., & Saudou, F. (2006) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-006-6242-0 · Cited by 241
Experimental therapeutics in transgenic mouse models of Huntington's disease
Beal, M. F., & Ferrante, R. J. (2004) · Nature reviews. Neuroscience · doi:10.1038/nrn1386 · Cited by 227
Self-citationA randomized clinical trial of coenzyme Q 10 and GPI-1485 in early Parkinson disease
The NINDS NET-PD Investigators (2007) · Neurology · doi:10.1212/01.wnl.0000250355.28474.8e · Cited by 220
Neurobehavioral assessment in the information age
Tecott, L. H., & Nestler, E. J. (2004) · Nature Neuroscience · doi:10.1038/nn1225 · Cited by 221
Excitotoxic Neuronal Death and the Pathogenesis of Huntington's Disease
Estrada‐Sánchez, A. M., Mejía-Toiber, J., & Massieu, L. (2008) · Archives of Medical Research · doi:10.1016/j.arcmed.2007.11.011 · Cited by 213
Li, J. Y., Popović, N., & Brundin, P. (2005) · NeuroRx · doi:10.1602/neurorx.2.3.447 · Cited by 221
Klivènyi, P., Kiaei, M., Gardian, G., Calingasan, N. Y., & Beal, M. F. (2003) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.2003.02160.x · Cited by 201
Self-citationFerrante, R. J., Ryu, H., Kubilus, J. K., D’Mello, S. R., Sugars, K. L., Lee, J.-H., Lu, P., Smith, K., Browne, S. E., Beal, M. F., et al. (2004) · Journal of Neuroscience · doi:10.1523/jneurosci.2599-04.2004 · Cited by 195
Self-citationCoenzyme Q10 effects in neurodegenerative disease
Henchcliffe, C. (2009) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s5212 · Cited by 189
The Melatonin MT1 Receptor Axis Modulates Mutant Huntingtin-Mediated Toxicity
Wang, X., Sirianni, A. C., Pei, Z., Cormier, K., Smith, K., Jiang, J., Zhou, S., Wang, H., Zhao, R., Yano, H., et al. (2011) · Journal of Neuroscience · doi:10.1523/jneurosci.3059-11.2011 · Cited by 186
Self-citationLee, D.-W., Shim, M. S., Keun-young Kim, A., Noh, Y. H., Kim, H., Kim, S. Y., Weinreb, R. N., & Ju, W. (2014) · Investigative Ophthalmology & Visual Science · doi:10.1167/iovs.13-12564 · Cited by 182
The pathogenic mechanisms of polyglutamine diseases and current therapeutic strategies
Bauer, P. O., & Nukina, N. (2009) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2009.06302.x · Cited by 178
Increased Susceptibility of Striatal Mitochondria to Calcium-Induced Permeability Transition
Brustovetsky, N., Brustovetsky, T., Purl, K. J., Capano, M., Crompton, M., & Dubinsky, J. M. (2003) · Journal of Neuroscience · doi:10.1523/jneurosci.23-12-04858.2003 · Cited by 179
Mitochondria and Huntington's Disease Pathogenesis: Insight from Genetic and Chemical Models
Browne, S. E. (2008) · Annals of the New York Academy of Sciences · doi:10.1196/annals.1427.018 · Cited by 176
Phosphorylation of profilin by ROCK1 regulates polyglutamine aggregation
Shao, J., Welch, W. J., DiProspero, N. A., & Diamond, M. I. (2008) · Molecular and Cellular Biology · doi:10.1128/mcb.00079-08 · Cited by 171
Minocycline and doxycycline are not beneficial in a model of Huntington's disease
Smith, D. L., Woodman, B., Mahal, A., Sathasivam, K., Ghazi‐Noori, S., Lowden, P. A. S., Bates, G. P., & Hockly, E. (2003) · Annals of Neurology · doi:10.1002/ana.10614 · Cited by 173
Stack, C., Ho, D. J., Wille, E. J., Calingasan, N. Y., Williams, C. R., Liby, K. T., Sporn, M. B., Dumont, M., & Beal, M. F. (2010) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2010.03.017 · Cited by 175
Self-citationDedeoglu, A., Kubilus, J. K., Yang, L., Ferrante, K. L., Hersch, S. M., Beal, M. F., & Ferrante, A. R. J. (2003) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.2003.01706.x · Cited by 169
Self-citationEvidence of Oxidant Damage in Huntington's Disease: Translational Strategies Using Antioxidants
Stack, E. C., Matson, W. R., & Ferrante, R. J. (2008) · Annals of the New York Academy of Sciences · doi:10.1196/annals.1427.008 · Cited by 169
Self-citationTherapeutic Advances for Huntington’s Disease
Kumar, A., Kumar, V., Singh, K., Kumar, S., Kim, Y.-S., Lee, Y.-M., & Kim, J.-J. (2020) · Brain Sciences · doi:10.3390/brainsci10010043 · Cited by 170
Dumont, M., Kipiani, K., Yu, F., Wille, E. J., Katz, M., Calingasan, N. Y., Gouras, G. K., Lin, M. T. S., & Beal, M. F. (2011) · Journal of Alzheimer s Disease · doi:10.3233/jad-2011-110209 · Cited by 163
Self-citationJohri, A., Calingasan, N. Y., Hennessey, T., Sharma, A., Yang, L., Wille, E. J., Chandra, A., & Beal, M. F. (2011) · Human Molecular Genetics · doi:10.1093/hmg/ddr541 · Cited by 163
Self-citationAntioxidants in Huntington's disease
Johri, A., & Beal, M. F. (2011) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2011.11.014 · Cited by 163
Self-citationFrom Pathogenesis to Therapeutics: A Review of 150 Years of Huntington’s Disease Research
Jiang, A., Handley, R. R., Lehnert, K., & Snell, R. G. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241613021 · Cited by 174
Therapeutic effects of coenzyme Q 10 (CoQ 10 ) and reduced CoQ 10 in the MPTP model of Parkinsonism
Cléren, C., Yang, L., Lorenzo, B. J., Calingasan, N. Y., Schomer, A. C., Sireci, A. N., Wille, E. J., & Beal, M. F. (2007) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2007.05097.x · Cited by 158
Self-citationClinical Potential of Minocycline for Neurodegenerative Disorders
BLUM, D., CHTARTO, A., TENENBAUM, L., BROTCHI, J., & LEVIVIER, M. (2004) · Neurobiology of Disease · doi:10.1016/j.nbd.2004.07.012 · Cited by 157
Gene expression in Huntington's disease skeletal muscle: a potential biomarker
Strand, A. D., Aragaki, A. K., Shaw, D., Bird, T. D., Holton, J. L., Turner, C., Tapscott, S. J., Tabrizi, S. J., Schapira, A. H. V., Kooperberg, C. L., et al. (2005) · Human Molecular Genetics · doi:10.1093/hmg/ddi192 · Cited by 160
Assessment of the nutrition status of patients with Huntington's disease
Contreras, A. T., Tarrats, R. M., Alonso, M. E., Boll, M., Ochoa, A., & Velásquez, L. (2004) · Nutrition · doi:10.1016/j.nut.2003.10.007 · Cited by 156
Polyglutamine Diseases: Where does Toxicity Come from? What is Toxicity? Where are We Going?
Takahashi, T., Katada, S., & Onodera, O. (2010) · Journal of Molecular Cell Biology · doi:10.1093/jmcb/mjq005 · Cited by 157
Rodent genetic models of Huntington disease
Heng, M. Y., Detloff, P. J., & Albin, R. L. (2008) · Neurobiology of Disease · doi:10.1016/j.nbd.2008.06.005 · Cited by 152
Chakraborty, J., Singh, R. P., Dutta, D., Naskar, A., Rajamma, U., & Mohanakumar, K. P. (2013) · CNS Neuroscience & Therapeutics · doi:10.1111/cns.12189 · Cited by 145
Simmons, D. A., Belichenko, N. P., Yang, T., Condon, C., Monbureau, M., Shamloo, M., Jing, D., Massa, S. M., & Longo, F. M. (2013) · Journal of Neuroscience · doi:10.1523/jneurosci.1310-13.2013 · Cited by 145
Noh, Y. H., Kim, K., Shim, M. S., Choi, S.-H., Choi, S., Ellisman, M. H., Weinreb, R. N., Perkins, G. A., & Ju, W.-K. (2013) · Cell Death and Disease · doi:10.1038/cddis.2013.341 · Cited by 146
Nucci, C., Tartaglione, R., Cerulli, A., Mancino, R., Spanò, A., Cavaliere, F., Rombolà, L., Bagetta, G., Corasaniti, M. T., & Morrone, L. A. (2007) · International review of neurobiology · doi:10.1016/s0074-7742(07)82022-8 · Cited by 143
A randomized, double-blind, placebo-controlled trial of coenzyme Q10 in Huntington disease
McGarry, A. J., McDermott, M., Kieburtz, K. D., de Blieck, E. A., Beal, F. M., Marder, K. S., Ross, C. A., Shoulson, I., Gilbert, P. R., Mallonee, W. M., et al. (2016) · Neurology · doi:10.1212/wnl.0000000000003478 · Cited by 139
Mitochondria targeted therapeutic approaches in Parkinson's and Huntington's diseases
Chaturvedi, R. K., & Beal, M. F. (2012) · Molecular and Cellular Neuroscience · doi:10.1016/j.mcn.2012.11.011 · Cited by 139
Self-citationPouladi, M. A., Stanek, L. M., Xie, Y., Franciosi, S., Southwell, A. L., Deng, Y., Butland, S. L., Zhang, W., Cheng, S. H., Shihabuddin, L. S., et al. (2012) · Human Molecular Genetics · doi:10.1093/hmg/dds037 · Cited by 144
Solans, A., Zambrano, A., Rodríguez, M., & Barrientos, A. (2006) · Human Molecular Genetics · doi:10.1093/hmg/ddl248 · Cited by 142
Therapeutic use of coenzyme Q 10 and coenzyme Q 10 -related compounds and formulations
Villalba, J. M., Parrado‐Fernández, C., González, M. S., & Alcain, F. J. (2010) · Expert Opinion on Investigational Drugs · doi:10.1517/13543781003727495 · Cited by 139
Cardiac dysfunction in the R6/2 mouse model of Huntington’s disease
Mihm, M. J., Amann, D. M., Schanbacher, B. L., Altschuld, R. A., Bauer, J. A., & Hoyt, K. R. (2006) · Neurobiology of Disease · doi:10.1016/j.nbd.2006.09.016 · Cited by 136
Dose ranging and efficacy study of high-dose coenzyme Q10 formulations in Huntington's disease mice
Smith, K. M., Matson, S., Matson, W. R., Cormier, K., Del Signore, S. J., Hagerty, S. W., Stack, E. C., Ryu, H., & Ferrante, R. J. (2006) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2006.03.004 · Cited by 127
Self-citationPathophysiology of Huntingtonʼs disease: from huntingtin functions to potential treatments
Roze, E. F., Saudou, F., & Caboche, J. (2008) · Current Opinion in Neurology · doi:10.1097/wco.0b013e328304b692 · Cited by 131
Mitochondria as targets for chemotherapy
Gogvadze, V. G., Orrenius, S., & Zhivotovsky, B. (2009) · APOPTOSIS · doi:10.1007/s10495-009-0323-0 · Cited by 127
Zhang, H., Li, Q., Graham, R. K., Slow, E., Hayden, M. R., & Борисович, Б. И. (2008) · Neurobiology of Disease · doi:10.1016/j.nbd.2008.03.010 · Cited by 127
(2018) · Handbook of Clinical Neurology · doi:10.1016/b978-0-444-63233-3.00017-8 · Cited by 122
Shehadeh, J., Fernandes, H. B., Mullins, M. Z., Graham, R. K., Leavitt, B. R., Hayden, M. R., & Raymond, L. A. (2005) · Neurobiology of Disease · doi:10.1016/j.nbd.2005.08.001 · Cited by 120
Bolaños, J. P., Moro, M. Á., Lizasoaín, I., & Almeida, Á. (2009) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2009.05.009 · Cited by 120
Oxidative stress in Niemann–Pick disease, type C
Fu, R., Yanjanin, N. M., Bianconi, S. E., Pavan, W. J., & Porter, F. D. (2010) · Molecular Genetics and Metabolism · doi:10.1016/j.ymgme.2010.06.018 · Cited by 117
Combination therapy using minocycline and coenzyme Q10 in R6/2 transgenic Huntington's disease mice
Stack, E. C., Smith, K. M., Ryu, H., Cormier, K., Chen, M., Hagerty, S. W., Del Signore, S. J., Cudkowicz, M. E., Friedlander, R. M., & Ferrante, R. J. (2006) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2005.11.002 · Cited by 114
Self-citationZádori, D., Nyíri, G., Szőnyi, A., Szatmári, I., Fülöp, F., Toldi, J., Freund, T. F., Vécsei, L., & Klivènyi, P. (2010) · Journal of Neural Transmission · doi:10.1007/s00702-010-0573-6 · Cited by 112
Martinelli, C., Pucci, C., Battaglini, M., Marino, A., & Ciofani, G. (2019) · Advanced Healthcare Materials · doi:10.1002/adhm.201901589 · Cited by 114
Chopra, V., Fox, J. H., Lieberman, G., Dorsey, K., Matson, W. R., Waldmeier, P. C., Housman, D. E., Kazantsev, A. G., Young, A. B., & Hersch, S. M. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0707842104 · Cited by 108
Self-citationMo, C., Hannan, A. J., & Renoir, T. (2015) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2015.03.003 · Cited by 108
Huntington Disease and the Huntingtin Protein
Zheng, Z., & Diamond, M. I. (2012) · Progress in molecular biology and translational science · doi:10.1016/b978-0-12-385883-2.00010-2 · Cited by 118
Excitotoxicity as a Target Against Neurodegenerative Processes
Binvignat, O., & Olloquequi, J. (2020) · Current Pharmaceutical Design · doi:10.2174/1381612826666200113162641 · Cited by 100
Mouse models of Huntington disease: variations on a theme
Ehrnhoefer, D. E., Butland, S. L., Pouladi, M. A., & Hayden, M. R. (2009) · Disease Models & Mechanisms · doi:10.1242/dmm.002451 · Cited by 100
Giralt, A., Carretón, O., Lao‐Peregrín, C., Martín, E. D., & Alberch, J. (2011) · Molecular Neurodegeneration · doi:10.1186/1750-1326-6-71 · Cited by 104
MacDonald, M. E., Ginés, S., Gusella, J. F., & Wheeler, V. C. (2003) · NeuroMolecular Medicine · doi:10.1385/nmm:4:1-2:7 · Cited by 104
The role of oxidative stress in Huntington’s disease: Are antioxidants good therapeutic candidates?
Gil-Mohapel, J., Brocardo, P., & Christie, B. (2014) · Current Drug Targets · doi:10.2174/1389450115666140115113734 · Cited by 101
Magaña, J. J., Velázquez‐Pérez, L., & Cisneros, B. (2012) · Molecular Neurobiology · doi:10.1007/s12035-012-8348-8 · Cited by 97
Evaluation of Coenzyme Q as an Antioxidant Strategy for Alzheimer's Disease
Wadsworth, T. L., Bishop, J. A., Pappu, A. S., Woltjer, R. L., & Quinn, J. F. (2008) · Journal of Alzheimer s Disease · doi:10.3233/jad-2008-14210 · Cited by 95
Modelling brain diseases in mice: the challenges of design and analysis
Watase, K., & Zoghbi, H. Y. (2003) · Nature Reviews Genetics · doi:10.1038/nrg1045 · Cited by 94
Cellular Consequences of Coenzyme Q10 Deficiency in Neurodegeneration of the Retina and Brain
Manzar, H., Abdulhussein, D., Yap, T. E., & Cordeiro, M. F. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21239299 · Cited by 97
Metadata
- Authors
- Ferrante, R. J., Andreassen, O. A., Dedeoglu, A., Ferrante, K. L., Jenkins, B. G., Hersch, S. M., & Beal, M. F.
- Affiliations
- Boston University (US)
- NewYork–Presbyterian Hospital (US)
- Harvard University (US)
- Venue
- The Journal of Neuroscience
- Publisher
- Society for Neuroscience
- Published
- 2002-03-01
- Volume
- 22
- Issue
- 5
- Pages
- 1592-1599
- ISSN
- 0270-6474 (ISSN-L)
- 1529-2401
- PMC
- PMC6758854
- OpenAlex
- W1949056714
- Cited by
- 391
- References
- 50
- Citations by year
- 2025: 8 · 2024: 8 · 2023: 7 · 2022: 6 · 2021: 7 · 2020: 10 · 2019: 9 · 2018: 12 · 2017: 7 · 2016: 12 · 2015: 8 · 2014: 23 · 2013: 11 · 2012: 23
- FWCI
- 12.48
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Journal of Neuroscience (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Institutes of Health (5r29ns037102-02)
- National Institute on Aging (AG 12992, AG 13846, P30AG013846, P01AG012992)
- National Institute of Neurological Disorders and Stroke (NS37102, NS 35255, NS38180, R01NS035255)
- National Center for Complementary and Integrative Health (AT00613, R01AT000613, U01AT000613)
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Genetic Neurodegenerative Diseases
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Coenzyme Q10 studies and effects
- Life Sciences › Neuroscience › Neurology › Neurological diseases and metabolism
- Keywords
- Huntington's disease, coenzyme Q10, remacemide, R6/2 transgenic mice, mitochondrial bioenergetics, excitotoxicity, NMDA receptor antagonism, neuronal intranuclear inclusions, brain atrophy, ventriculomegaly, motor impairment, combination therapy, survival extension
- MeSH terms
- Huntingtin Protein, Acetamides, Administration, Oral, Animals, Behavior, Animal, Body Weight, Brain, Cerebral Ventricles, Coenzymes, Disease Models, Animal, Drug Evaluation, Preclinical, Drug Synergism, Female, Humans, Huntington Disease, Magnetic Resonance Imaging, Male, Mice, Transgenic, Motor Activity, Nerve Tissue Proteins, Nuclear Proteins, Organ Size, Ubiquinone, Survival Rate, Treatment Outcome, Disease Progression, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
